| 摘要 |
An adenylate cyclase type IV protein, cDNA, and reagents which regulate human adenylate cyclase type IV can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, diseases that are caused by aberrant activity of this enzyme and diseases whose symptoms can be ameliorated by stimulating or inhibiting the activity of type IV adenylyl cyclase. Such diseases include, for example, hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; restenosis; atherosclerosis; diseases characterized by excessive smooth muscle cells or reduced smooth muscle cell proliferation; aneurysms; wound healing; stroke; ischemia; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic; and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation, degenerative diseases, such as neurodegenerative diseases and dyskinesias, among others. |
